|
(Health-NewsWire.Net, October 29, 2021 )
Market Overview
Zoladex is an injectable gonadotropin-releasing hormone agonist (GnRH agonist) medication used to suppress the production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast and prostate cancer.
View full report: https://bit.ly/3110san
Market Dynamics
Increasing prevalence of breast cancer associated with infertility due to chemotherapy is driving the market growth
Increasing prevalence of breast cancer associated with infertility due to chemotherapy is driving the market growth. It is estimated that in the United States, around 276,480 new cases of invasive breast cancer would be diagnosed in women. For the treatment, many breast cancer patients undergo chemotherapy based on the stage of cancer. Because of chemotherapy, there are chances of infertility.
Moreover, fertility after chemotherapy depends on patients' age and the types and doses of the patients' chemotherapy medicines. As every woman ages, her ovaries produce fewer fertile eggs. When the woman goes into menopause, her ovaries stop making fertile eggs. Women treated for cancer younger than age 30 have the best chance of becoming pregnant after chemotherapy.
Overall, the younger the woman is, the more likely her ovaries will produce fertile eggs after chemotherapy. In addition, certain chemotherapy medicines are more likely than others to cause infertility, including Cytoxan (chemical name: cyclophosphamide). Platinol (chemical name: cisplatin) and Adriamycin (chemical name: doxorubicin) carry a medium risk of losing fertility.
Researchers were looking at ovarian suppression — stopping ovarian function using medicine — to help protect a woman's eggs during chemotherapy. But there was less information available. For instance, a study suggests that premenopausal women diagnosed with hormone-receptor-negative, early-stage breast cancer treated with Zoladex while getting chemotherapy before breast cancer surgery were much less likely to be infertile after breast cancer surgery chemotherapy ended.
Market Segmentation:
By Product type
• 3.6mg
• 10.8mg
By Application
• Prostate Cancer
• Breast Cancer
• Endometriosis
• Others
Download free sample: https://bit.ly/3EohM7G
Geographical Analysis
North America region holds the largest market share in the global zoladex market.
North America accounted for the largest revenue share in 2020, owing to the high prevalence of prostate cancer in the region and increasing awareness among people about the drug. For instance, according to the American Cancer Society, Prostate cancer is the second leading cause of cancer death in American men.
The estimates for prostate cancer in the United States for 2021 are about 248,530 new cases of prostate cancer and about 34,130 deaths from prostate cancer. Moreover, about 1 man in 8 will be diagnosed with prostate cancer during his lifetime and is more likely to develop in older men and non-Hispanic Black men. About 6 cases in 10 are diagnosed in men who are 65 or older, and it is rare in men under 40.
The average age of men at diagnosis is about 66. Therefore, it leads to an increase in the demand for Zoladex, which is expected to hold the largest market share in the North American region over the forecast period.
Competitive Landscape
The zoladex market is highly competitive with presence of local as well as global players. Some of the key players which are contributing to the growth of the market include AstraZeneca Plc, Eli Lilly and Company, Bayer HealthCare Pharmaceuticals, Inc, Abbott Laboratories, Pfizer, Inc, Neurocrine Biosciences, Inc, Meditrina Pharmaceuticals, Inc and AEterna Zentaris, Inc.
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the zoladex market globally.
Trending Topic's, Artemisinin Combination Therapy Market, Tapentadol Market, Chondroitin Sulfate Market, Benzodiazepine Drugs Market, Dysthymia Drugs Market
DataM Intelligence
Sai Kiran
+1 877 441 4866
pr@datamintelligence.com
Source: EmailWire.Com 
|
